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Abstract
Thymic epithelium, including nurse cells (TEC/TNC), as
well as other thymic stromal cells (macrophages and
dentritic cells), express a repertoire of polypeptide be-
longing to various neuroendocrine protein families (such
as the neurophypophysial, tachykinin, neurotensin and
insulin families). A hierarchy of dominance exists in the
organization of the thymic repertoire of neuroendocrine
precursors. Oxytocin (OT) is more expressed in the TEC/
TNC than vasopressin (VP); insulin-like growth factor 2
(IGF-2) thymic expression predominates over IGF-1, and
much more over (pro)insulin. Thus, OT was proposed to
be the self antigen of the neurohypophysial family, and
IGF-2 the self antigen precursor of the insulin family. The
dual role of the thymus in T-cell life and death is recapitu-
lated at the level of the thymic neuroendocrine protein
repertoire. Indeed, thymic polypeptides behave as acces-
sory signals involved in T-cell development and positive
selection according to the cryptocrine model of signal-
ing. Moreover, thymic neuroendocrine polypeptides are
the source of self antigens presented by thymic MHC
molecules to developing pre-T cells. This presentation
might induce the negative selection of T cells bearing a
randomly rearranged antigen receptor (TCR) oriented
against neuroendocrine families. Using an animal model
of autoimmune type 1 diabetes (BB rat), we have shown
a defect in intrathymic expression of the self antigen of
the insulin family (IGF-2) and in IGF-2-mediated T-cell
education to recognize and tolerate the insulin family.
Altogether these studies have enlighted the crucial role
played by the thymus in the induction of the central self
tolerance of neuroendocrine families. The tolerogenic
properties of thymic self peptides could be used in a nov-
el type of vaccination for the prevention of autoimmune
diseases.
Introduction
For a long time the thymus was considered to be an
intrinsic component of the endocrine system though the
endocrine model of cell-to-cell signalling had not been ful-
ly validated for this organ. With the discovery of its pri-
mary role in T-lymphopoiesis [1], the endocrine role of
the thymus progressively vanished. In the past 15 years,
the question of a neuroendocrine component in thymic
physiology was reinvestigated. From a number of studies,
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it now appears that the thymus represents a crucial site for
a cross-talk between the neuroendocrine and immune sys-
tems, in particular during fetal development. Thymic epi-
thelial and stromal cells express a repertoire of neuroen-
docrine-related genes/protein precursors. It was shown
that thymic polypeptides may serve as signals interacting
with their cognate neuroendocrine receptors on develop-
ing pre-T lymphocytes. This cryptocrine form of cell-to-
cell signaling could play a role in T-cell development and
maturation. On the other side, there is ample evidence
that thymic neuroendocrine-related polypeptides also be-
have as a source of self antigens which are presented to
pre-T cells and are thought to induce the negative selec-
tion of T cells bearing a randomly rearranged antigen
receptor (TCR) oriented against endogenous neuroendo-
crine families (self-reactive T cells). The objective of this
review is to expose most of the scientific arguments which
support the important role of the thymus in the education
of T lymphocytes to recognize and tolerate neuroendo-
crine functions.
The Establishment of Immunological Self
Tolerance
The process of self tolerance induction involves a mul-
tilayered organization in which various tolerizing mecha-
nisms are interconnected in series, from the early steps in
immune cell ontogeny to an advanced stage in life [2].
With regard to the T-lymphocyte system, the primary
tolerizing steps occur within the thymus, the primary lym-
phoid organ responsible for T-cell differentiation. To
complete their differentiative program, immature T cells
receive a series of signals from the thymic cellular mi-
croenvironment. Such activatory signals may be emitted
by thymic stromal cells (like hormones or cytokines) or
may result from direct interactions between cell adhesion
molecules expressed on pre-T cells (thymocytes) and
thymic stromal cells [3, 4]. Along their differentiation,
immature T cells randomly rearranged the genes coding
for the segments of their TCR. A lot of these random TCR
combinations are oriented against self antigens which are
expressed in the thymic microenvironment, then present-
ed by proteins encoded in the major histocompatibility
complex (MHC). The interaction of self-reactive T-cell
clones with their cognate self antigens is thought to lead to
their negative selection either by programmed cell death
(apoptosis), or by their developmental arrest. This process
of thymic clonal deletion was demonstrated with the use
of MMTV (mouse mammary tumor virus)-encoded su-
perantigens [5], and with transgenic mice expressing a
TCR specific for the male antigen H-Y [6]. Since the thy-
mus does not express all the components of the self struc-
ture, this organ does not delete all potential autoreactive T
cells. Consequently, the existence of other tolerizing
mechanisms (such as T-cell anergy) at the periphery was
postulated, and they were effectively shown to intervene
in the process of immunological self tolerance. Neverthe-
less, thymic clonal deletion of self-reactive T cells is by far
the most important mechanism involved in self education
of the immune system [7].
Thymic T-Cell Life and Death
Self peptides are not only involved in the induction of
central T-cell self tolerance but they also intervene in the
process of T-cell maturation or positive selection [8].
Thus, the thymus is the site for an important paradox of
contemporary cell biology: How can T lymphocytes be
both positively and negatively selected in the thymic
microenvironment [9]? A first explanation proposed that
thymic epithelial cells (TEC) were responsible for T-cell-
positive selection, whereas other thymic bone-marrow-
derived stromal cells (macrophages and dendritic/interdi-
gitating (IDC) cells) induced deletion of self-reactive T-
cell clones [10]. However, this hypothesis is no longer sup-
ported by recent experiments which have established that
TEC are able to delete self-reactive T cells (see after). The
‘avidity/affinity hypothesis’ has been proposed as another
explanation of the thymic paradox [11, 12]. This hypothe-
sis is based on experiments showing that transgenic TCRs
(specific for defined antigens) do not mature in organ cul-
tures of fetal thymuses from MHC class I-defective ani-
mals. However, they do so if peptides related to the cog-
nate antigen of TCR are added in the cultures. So T lym-
phocytes are positively selected if their TCR is barely
engaged with self peptide presented by MHC ligands, and
they are deleted if their TCR is strongly engaged. How-
ever, since the usual affinity of a TCR for its cognate anti-
gen is already rather low (10–8 M at the maximum), one
may question the importance of the biological effects
mediated by a lower affinity. If the experiments men-
tioned above have convincingly shown that T-cell positive
selection is peptide-specific and depends on ligand con-
centration, one may also question the nature and the
amount of peptide/MHC combinations that contribute in
vivo to positive selection of a particular TCR in a normal
thymus. Because of their high polymorphism, thymic
molecules derived from MHC cannot establish the dis-
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crimination between self and nonself antigens. Given the
hazardous nature of the recombination of TCR gene seg-
ments, the precise identity of thymic peptides supporting
T-cell positive and negative selection has become an
important current question [13].
Thymic Neurohypophysial-Related Peptides
At the beginning of this century, Ott and Scott [14]
described the galactogogue activity of thymic extracts
after injection into the goat. At that time, oxytocin (OT)
had not been identified as the primary mediator of the
galactokinesis and the oxytocic activity of thymic extracts
was not further characterized. TEC and thymic nurse cells
(TNC) from different species synthesize polypeptide pre-
cursors of the neurohypophysial family, with a domi-
nance of the OT lineage [15–21]. The oxytocic action of
human fetal thymic extracts was also described [22]. TNC
in the subcapsular and outer cortex of thymic lobules con-
stitute an intimate neuroendocrine-immune microenvi-
ronment since their epithelial component (but not the
TNC-engulfed pre-T cells) produces neurohypophysial-
related peptides and expresses the phenotype of neuroen-
docrine cell types [23]. Transcripts of proOT and proVP
were detected both in human [17] and murine [24] thymic
extracts, and the intrathymic expression of neurohypo-
physial genes during ontogeny is under current investiga-
tion. However, the synthesis of OT in TEC/TNC is not
coupled with the secretion of the nonapeptide or its neu-
rophysin in the supernatant of human TEC/TNC primary
cultures. As shown in the murine thymus, immunoreac-
tive (ir)-OT is not located in secretory granules but is dif-
fuse in the cytosol, in vesicles of the endoplasmic reticu-
lum, and associated with keratin filaments [25]. Interest-
ingly, similar ultrastructural features were also reported
for OT and VP expressed by murine spleen eosinophil-
like cells [26].
As discussed above, the thymic function is closely asso-
ciated with the presentation of the self molecular structure
to developing T cells. This action was long thought to be
mediated by thymic macrophages and IDC only, but there
is now large evidence that TEC/TNC are actively in-
volved in the induction of central self tolerance [97, 98].
Using the appropriate methodology, we provided evi-
dence that the presentation of thymic OT implicates a
hybrid 55-kD protein probably bearing a neurophysin
(10 kD) and a MHC class I heavy chain domain (45 kD)
[29]. Following this putative explanation, the MHC class I
domain would be implicated in membrane targeting of
this hybrid protein, whereas neurophysin could bind OT
for presentation to pre-T cells. In relationship with our
studies, other authors have shown the translocation of a
neurophysin-like material in the cell membranes of cancer
cells. They also provided several arguments supporting
the behavior of neurohypophysial-related peptides as can-
didate tumoral antigens [30, 31]. Thus, both in the hypo-
thalamo-neurohypophysial axis and in the thymus, the
neurophysin part of the OT precursor fulfills the same
function: binding of the active nonapeptide OT and trans-
port to the external limit of neurons or TEC/TNC. The
tyrosine residue in position 2 of OT and VP plays an
important role in their binding to neurophysin [32]. Inter-
estingly, the residue tyrosine in the same position was
found to play a crucial role in the binding of antigens to
some MHC class I alleles for their presentation [33].
As another argument for an antigenic role of thymic
OT, we have shown that the immunological recognition of
OT by specific mAbs at the outer surface of human TEC
plasma membrane induced a marked secretion of the
cytokines interleukin(IL)-6 and leukemia inhibitory fac-
tor (LIF) in the supernatant of TEC cultures [34]. Given
the nature of the epitopes recognized by anti-OT mAbs,
we were able to conclude that thymic OT is fully pro-
cessed at the level of the TEC plasma membrane. The
absence of biological effects following the treatment of
TEC cultures with anti-VP mAbs supports our hypothesis
that thymic OT behaves as the self antigen of the neurohy-
pophysial hormone family.
Intrathymic Cryptocrine Signaling
The model of cell-to-cell cryptocrine signaling has been
proposed by Funder [35] to characterize the direct mem-
brane-to-membrane exchange of chemical information
between large epithelial nursing cells and immature ele-
ments which migrate and differentiate at their contact.
Besides its role as a self antigen, there is also evidence that
OT mediates a cryptocrine-type signaling between TEC/
TNC and pre-T cells. Neurohypophysial peptide recep-
tors have been detected in the rat thymus and on rat thy-
mocytes [36, 37], on a murine pre-T cell line (RL12-NP)
[38] and on murine cytotoxic T cells [38, 39]. Estrogens
were shown to increase the affinity of OT receptors in the
rat thymus [40]. Interestingly, the expression of the rat
V1b (or V3) receptor was recently identified in tissues
outside the anterior pituitary, including the thymus [41].
Already in 1969, the mitogenic effect of neurohypophy-
sial peptides on rat thymocytes was described [42], where-
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as OT was reported to stimulate glucose oxidation by rat
thymocytes [43]. On the basis of antagonist effects, mu-
rine pre-T cells express a V1 (or V3) subtype of neurohy-
pophysial receptor, while mature cytotoxic T cells harbor
receptors of the OT type; this observation suggests that
the neurohypophysial reception system expressed by T
lymphocytes could ‘mature’ in parallel with their stage of
differentiation. In both of T-cell types, neurohypophysial
peptide receptors transduce OT and VP via the phospho-
inositide pathway and neurohypophysial-related signals
increase the incorporation of tritiated thymidine by fresh-
ly isolated murine thymocytes suggesting a mitogenic
effet [38]. Western blots of RL12-NP-extracted proteins
with anti-phosphotyrosine revealed a number of proteins
the phosphorylation of which was stimulated either by
OT or VP. Two of these proteins were precipitated with
anti-focal adhesion (FAK) mAb 2A7 and were identified
one as p125FAK and the other as a co-precipitating 130-kD
protein (probably p130Cas). Another protein phosphory-
lated by OT in RL12-NP cells was identified as paxillin, a
68-kD protein located at focal adhesion sites and associat-
ed with p125FAK. Interestingly, OT was more potent than
VP in inducing p125FAK phosphorylation and this OT
effect was inhibited by a V1 receptor antagonist, confirm-
ing that immature T cells bear a V1-type neurohypophy-
sial receptor [44]. Stimulation of focal adhesions could
play an important role in promoting T-cell interactions
with the thymic cellular microenvironment which are
fundamental for the T-cell differentiation programme.
There is thus large experimental evidence that thymic OT
mediates a functional cryptocrine signaling that could
serve as an accessory pathway in the positive selection of
T cells.
The existence of a functional signaling between thymic
OT and neurohypophysial receptors expressed by imma-
ture and cytotoxic T cells raises the possibility of a phar-
macological modulation of T-cell activity by OT receptor
antagonists. Using the methodology of whole blood cell
cultures, OT hexapeptide antagonists (developed by
Merck Sharp & Dohme Research Laboratories) were
shown to inhibit the production of IL-1ß and IL-6 elicited
by human T-cell activation with anti-CD3 mAb [45]. Spe-
cific antagonists of OT receptors expressed by immune
cells could offer a therapeutic benefit in circumstances
during which an enhancement of the immune reactivity
and a relapse of autoimmune diseases are observed (such
as during the postpartum or during lactation).
Application to Other Neuroendocrine
Polypeptide Families
A number of neuroendocrine-related polypeptides
have been detected and characterized in TEC and thymic
stromal cells from different species (table 1). The well-
characterized neuropeptides neurotensin (NT) and soma-
tostatin have been extracted from the chicken thymus,
especially after hatching, and were characterized both
immunochemically and chromatographically [46]. We
have shown the expression of ir-NT at the cell surface of
human TEC. Cultured human TEC contain F5 ng ir-NT/
106 cells, of which 5% is associated with plasma cell mem-
branes. HPLC analysis of ir-NT present in human TEC
revealed a major peak of ir-NT corresponding to intact
NT1–13. Ir-NT was not detected in the supernatant of
human TEC primary cultures. Using an affinity column
prepared with an anti-MHC class I Ab, NT-related pep-
tides were retained on the column and were eluted togeth-
er with MHC class I proteins [47].
Neurokinin A (NKA) is the peptide of the tachykinin
family encoded in human and rat TEC by the preprota-
chykinin A (PPT-A) gene [48]. Thymic PPT-A expression
was shown to be glucocorticoid-dependent since adrenal-
ectomy of Sprague-Dawley rats markedly enhanced the
levels of thymic PPT-A (and NPY) mRNAs [Ericsson and
Geenen, unpubl. data]. Interestingly, NKA exerts IL-1-
like mitogenic effects on murine thymocytes [49], and this
effect suggests the expression of specific tachykinin recep-
tors by immature T cells which could be implicated in
another accessory pathway for T-cell maturation and pos-
itive selection. The amino-acid sequence of NKA shares
the same C-terminal epitope with other members of the
tachykinin family, and the leucine residue in position 9
could be used in the binding to some MHC class I alleles,
thus making NKA the self antigen of the tachykinin fami-
ly. The other tachykinin encoded by PPT-A, substance P
(SP), is not detected in TEC but within sensory nerve
fibers of the thymus [50]. Thymic-specific receptors for
SP are associated with the vasculature in the medulla,
where they could control local blood flow and vascular
permeability [51].
The expression within the rat thymus of natriuretic
peptides (ANP, BNP and CNP) has been well docu-
mented. ANP seems to be the dominant thymic peptide
and is expressed by thymic macrophages, while ir-CNP
has been detected in thymocytes. The different types of
natriuretic peptide receptors were also detected by RT-
PCR [52, 53]. The treatment with ANP of murine fetal
thymic organ cultures (FTOC) was shown to decrease the
Neurohypophysial peptides
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Table 1. The thymic repertoire of neuroendocrine self peptides
Neuroendocrine families Physiological aspects Thymic repertoire






Insulin Glucose metabolism IGF-2 1 IGF-1 11 Insulin
Insulin-like growth factor 1 (IGF-1) Growth control
Insulin-like growth factor 2 (IGF-2) Fetal development
Parathormones
Parathormone (PTH) Calcium metabolism PTH-rP 11 PTH [106]
Parathormone-related peptide (PTH-rP)
Calcitonins
Calcitonin (CT) Calcium metabolism CGRP 11 CT [107]
Calcitonin gene-related peptide (CGRP)
Tachykinins













total thymocyte yield in FTOC, to increase the CD4–8–
and to decrease the CD4+8+ thymocyte subpopulations
[54].
It has to be mentioned that a series of anterior pituitary
hormone immunoreactivities have been detected in dif-
ferent TEC subpopulations of the human thymus. These
TEC populations were different from OT/VP/neurophy-
sin-containing epithelial cells. However, it is not yet clear
whether these hormones are locally synthesized or stored
in TEC from peripheral blood [55], though they were
identified in cultured rat thymic fragments [56].
Importantly, the expression of thymic hormones has
been shown to be under the control of the neuroendocrine
and steroid microenvironment [57], and this will be dis-
cussed in detail in another chapter.
Thymic Expression of Insulin-Related Genes
In the line of our working model that central T-cell tol-
erance of neuroendocrine functions is induced by the
thymic repertoire of neuroendocrine self antigens, a series
of investigations were undertaken to identify the domi-
nant member of the insulin family expressed in the thym-
ic microenvironment. By immunocytochemistry with a
panel of specific Abs directed against distinct epitopes of
the insulin family, ir-IGF-2 was clearly identified as the
dominant member of the insulin family expressed by
TEC/TNC [58]. A mAb against proinsulin [59] revealed a
slight labeling but outside thymic lobules, in the intersti-
tial tissue of the thymic capsule and in interlobular septae.
Thymic labeling was also negative with mAbs against the
C-terminal part of the insulin B chain. A few IGF-1-posi-
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tive cells were also stained in thymic lobules but they were
not epithelial; their distribution and morphology were
similar to those of macrophages. Of interest, murine mac-
rophages were shown to express IGF-1 Ea and Eb trans-
cripts [60]. Interferon-Á inhibits macropage IGF-1 at the
transcriptional level [61], whereas colony-stimulating fac-
tors induce IGF-1 mRNA [62]. Ir-IGF-2 was not detected
in the supernatant of human TEC primary cultures and,
with the use of confocal microscopy, a large part of ir-
IGF-2 was found to be associated with the outer surface of
TEC plasma membranes. This was not the case for either
IGF-1 or insulin. In the human thymus, IGF-2, IGF-1 and
(pro)insulin concentrations were respectively 96.7 B
10.6 ng/g, 42.9 B 5.0 ng/g, and !0.1 ng/g wet weight.
IGF2 transcripts have been isolated from whole human
thymic extracts, as well as from primary cultures of
human TEC. With RT-PCR and different specific prim-
ers, the expression of IGF2 in the human thymus was
found to be controlled by the same promoters as in other
fetal and adult extrahepatic tissues [63, 64, and Kecha et
al., submitted]. The effects of Igf2 overexpression under
the control of the MHC H-2Kb promoter have been inves-
tigated by the generation of transgenic mice. The highest
levels of transgene expression were found in thymus and
spleen. Only the thymus showed a significant increase of
weight in these transgenic mice, in agreement with the
high mRNA expression within this organ [65].
Going back to the initial observations made by Pansky
et al. [66], there is evidence that the thymic insulin-like
reticular factor isolated by them corresponds in fact to
IGF-2. The IGF-2 structure closely related to (pro)insulin
explains a cross-reactivity with the polyclonal Abs di-
rected against insulin that were used in 1965. The hypo-
glycemic properties of IGF-2 have been well described
[67] and might explain the biological activity of thymic
extracts on glucose metabolism. Moreover, the syndrome
of hypoglycemia and lymphoid leukemia associated with
thymic hyperplasia of some AKR female mice could in
fact result from the overexpression of Igf2 in hyperplastic
thymic epithelium, with a subsequent secretion of IGF-2
in the bloodstream, and a profoundly disturbed thymic
T-cell lymphopoiesis.
The hypothesis of a central T-cell tolerance of the insu-
lin family and, secondarily, of the peripheral insulin-
secreting pancreatic islet ß cells was further supported by
the observation that transcripts of proinsulin and of 67-
kD isoform of glutamic acid decarboxylase (GAD) genes
can be detected in the murine thymus with 30 cycles of
RT-PCR [68]. Thymic insulin gene (INS) expression was
highest in perinatal mice and persisted until 12 weeks of
age. Two recent papers confirmed these findings and
reported that INS transcripts, as well as (pro)insulin pro-
tein can be detected at very low levels (100–1,000 fmol/g
wet weight) in the human fetal thymus [69, 70]. The ques-
tion of an illegitimate INS trancription was ruled out by
the RIA detection of ir-(pro)insulin within thymic tissues.
Preliminary in situ hybridization studies have shown the
presence of INS transcripts within murine thymic IDC,
but the protein could not be evidenced by immunocyto-
chemistry [Homo-Delarche, pers. commun.].
A functional signaling mediated in the thymus by IGFs
and IGF receptors is highly plausible because type 1 and
type 2 IGF receptors have been detected on rat thymo-
cytes and murine thymoma cells [71], on human phytohe-
magglutinin A (PHA)-activated T cells and on anti-CD3-
activated human T lymphocytes [72, 73]. Kooijman et al.
[74] have described a differential expression of type 1 IGF
receptors in relation to the stage of activation and differ-
entiation of human T lymphocytes. Interestingly, in Igf2
transgenic mice, the increased thymic cellularity is associ-
ated with a stimulated generation of phenotypically nor-
mal T cells, in particular CD4 T cells [75]. In our hands,
specific type 2 IGF receptors were detected on a murine
immature T-cell line (RL12-NP), as well as on Jurkat T
cells [76]. By affinity cross-linking, the type 2 IGF recep-
tor expressed by lymphocytes was found to have a molec-
ular weight (B260 kD) similar to that found on other
cells. We currently investigate the biological action of
thymic IGFs on T-cell differentiation through the use of
murine FTOC and with specific Abs against IGF recep-
tors [Kecha et al., in preparation].
Some Principles and Advantages of Thymic
T-Cell Education to Neuroendocrine Self
Antigens
A model has been proposed according to which neu-
roendocrine-related thymic polypeptides engage two dis-
tinct types of interactions with pre-T cells depending on
their involvement as self antigens of their family or as
cryptocrine signals (table 2) [77]. The interaction of neu-
roendocrine self antigens with their corresponding TCR
implies a binding of moderate affinity (10–6 to 10–8 M),
but with a high power of discrimination. Neuroendocrine
self antigens usually correspond to peptide sequences of
neuroendocrine precursors which have been highly con-
served during the evolution of their related family. On the
other hand, cryptocrine signaling between thymic neu-
roendocrine-related peptides and their cognate receptors
Physiology
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expressed by pre-T cells implies a high-affinity binding
(10–10 to 10–11 M ), with a low discrimination. Moreover,
a hierarchy of dominance appears in the organization of
the polypeptide repertoire expressed in the thymus (ta-
ble 1). This is very significant since self tolerance primari-
ly concerns self determinants that are dominant on self
molecules [78–80].
Some selective advantages appear from this model of
thymic neuroendocrine-related precursors of cryptocrine
signals and self antigens in T-cell positive and negative
selection, respectively. A first advantage is the absence of
a tight allelic restriction in thymic T-cell education to neu-
roendocrine families. Such an allelic restriction of central
T-cell tolerance of neuroendocrine families was hardly
conceivable and our data seem to indicate that it is not the
case in reality. Concerning the presentation of thymic OT
for example, our data suggest that, though MHC class I
molecules are of course involved in the process, it is the
invariant neurophysin domain of the hybrid membrane
55-kD protein that binds OT for presentation to pre-T
cells. Another selective advantage resides in the potential
presentation to pre-T cells of the structure characteristic
of the neurohypophysial family. With regard to the thym-
ic presentation of NT, there is no physical constraint for a
non covalent binding to MHC since this neuropeptide is a
linear peptide (in contrast to cyclic OT and IGF-2). In
addition, the C-terminal sequence of NT includes tyro-
sine, isoleucine and leucine residues which can all be used
in the anchorage to most of the MHC class I alleles. Given
these characteristics, it is logical to postulate that NT and
NT-derived C-terminal fragments could behave as natu-
ral ligands for a majority (if not all) of MHC class I alleles.
This hypothesis is also in agrement with the high degree of
conservation of NT-related C-terminal region throughout
evolution [81].
For IGFs, the role of binding and transport proteins is
ensured by IGF-binding proteins (IGFBPs). IGFBPs have
co-evolved with IGFs but they are not part of IGF precur-
sors and are encoded by distinct genes. These proteins are
thought to play a prominent role in regulating the bio-
availability and distribution of IGFs [82, 83]. Interesting-
ly, some IGFBPs are in close relationship with cell plasma
membranes (through binding to integrins or the extracel-
lular matrix), but their relationship with MHC as well as
their potential implication in thymic IGF presentation to
immature T cells deserve to be further investigated.
Table 2. The dual role of thymic neuroendocrine self peptides in
T-cell differentiation
Cryptocrine signalling Presentation of neuroendocrine
self antigens
Physiology
Accessory signal in T-cell
development and activation
(positive selection)
T-cell education to neuro-
endocrine families
(negative selection of self-
reactive T cells)
Pathophysiology Pathophysiology
Oversecretion in the bloodstream
(paraneoplastic syndrome)
Involvement in the biology of
T-cell lymphomas














A Role Played by a Trouble in Thymic T-Cell
Education in Autoimmunity?
The development of an autoimmune disease affecting
the neuroendocrine system may be viewed as a failure to
develop or maintain tolerance to cellular or molecular
components which are constitutively expressed by neu-
roendocrine cells (i.e. autoantigens such as insulin or
GAD). In this view, a large body of research recently
focused on the physiological mechanisms which underline
the establishment of self tolerance and about the potential
factors leading to its breakdown in autoimmunity.
Though the relationship between lymphoepithelial struc-
tures and autoimmunity was suspected in 1962 by Burnet
and Mackay [84], the question of a defective thymic T-cell
negative selection or self education in the pathophysiolo-
gy of autoimmune diseases has not been intensively inves-
tigated. Nevertheless, it was shown that neonatal thymec-
tomy prevents the emergence of diabetes in an animal
model of autoimmune type 1 diabetes, the Bio-Breeding
(BB) rat [85]. In clinical practice also, thymectomy usually
induces an improvement of patients suffering from au-
toimmune myasthenia gravis, especially when a thymoma
(hyperplasia of thymic epithelium) is associated [86]. In
both cases, the benefit of thymectomy might in fact result
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from the removal of the defective thymic censorship
which is responsible for a continuous release and enrich-
ment of the peripheral T-cell pool with intolerant and self-
reactive lymphocytes. The development of diabetes is pre-
vented by the transplantation of thymus from diabetes-
resistant (DR) to diabetes-prone (DP) BB rats [87]. The
transplantation of the thymus from NOD mice to DR
mouse strains was also shown to induce diabetes in the
recipients [88]. While bone marrow transplantation is
rather ineffective in preventing autoimmune diseases of
MRL/+ mice, thymus transplantation is a crucial factor
for their prevention [89]. A defective process of thymic
T-cell negative selection has been suggested on the basis
that the thymus of DR BB rats contains thymocytes pre-
disposed to autoreactivity [90]. Another argument is the
observation that grafts of pure thymic epithelium from
NOD mouse embryos to newborn C57BL/6 athymic mice
induced CD4 and CD8 T-cell-mediated insulitis and siali-
tis [91]. At the histological level, a defect in thymic func-
tion could be linked to a disorganization of the microenvi-
ronment such as the giant perivascular spaces observed in
the NOD mouse thymus [92], and the epithelial defects of
BB rat thymus [93]. Recently, we examined the elution
profiles of ir-IGFs in the thymus from Wistar-Furth (WF)
normal rats, DR and DP BB rats. A peak of ir-IGF-2 1
10 ng/ml was observed in the G75 profile of WF thymus
extracts; a peak around 1.5 ng/ml was eluted from DR BB
rat thymic extracts, while IGF-2 concentrations were
almost undetectable in DP BB rats [94]. Altogether, these
observations support the hypothesis that a defective
thymic censorship or T-cell self education might well take
an active part in the pathophysiology of autoimmune type
1 diabetes.
Neuroendocrine Self Antigens versus
Autoantigens: Toward the Design of
Tolerogenic Vaccines for the Prevention of
Autoimmune Diseases?
Three types of factors are usually thought to be impli-
cated in the pathogeny of autoimmune diseases. (1) The
effector immune components are CD4- and CD8-auto-
reactive T cells which are specifically oriented against a
given target cell or molecule. These autoreactive T cells
result from a spontaneous breakdown of T-cell tolerance,
either at the central thymic and/or the peripheral level.
(2) A series of extra- and intra-MHC genes have been
demonstrated to be related to different autoimmune dis-
eases. Some of these genes could intervene in the presen-
tation of target autoantigens to autoreactive T lympho-
cytes, but others certainly not. (3) Finally, an environmen-
tal factor is involved and could be implicated in estab-
lishing a link between the target autoantigens and auto-
reactive T cells. A molecular mimicry between target
autoantigens and microorganisms might play at this level
and this hypothesis recently received some experimental
support [95]. The intervention of microbial superantigens
has also been proposed to activate peripheral autoreactive
T cells [96]. A preventive strategy of autoimmune diseases
can hardly been designed on the basis of the genetic com-
ponents of autoimmune disease or the hazardous environ-
mental factors. Manipulation of autoreactive T cells
seems to be a more promising way by which an efficient
prevention of autoimmunity can be envisioned.
In the neurohypophysial family, evidence has been
presented that OT seems to be the neurohypophysial self
antigen. A strong immunological tolerance protects the
OT lineage, more than the VP one, from an autoimmune
aggression. Indeed, some cases of idiopathic diabetes insi-
pidus have been shown to result from an autoimmune
hypothalamitis oriented toward VP-producing neurons
[97, 98]. Given the implication of the OT lineage in the
reproductive process, a stronger tolerance of this lineage is
important for the preservation of the species. Thus, in the
neurohypophysial family, while OT behaves as the self
antigen, VP is suspected to be one target autoantigen of
the autoimmune process. As discussed previously, this
conclusion is also supported by the frequence and the
titers of Abs induced by active immunization against neu-
rohypophysial peptides [VP 11 OT]. An infiltration of the
hypothalamo-neurohypophysial tract by inflammatory
mononuclear cells has been observed repeatedly, both
after active immunization against VP [99], and in sponta-
neous diabetes insipidus [98]. These observations suggest
that hypothalamic magnocellular neurons express on their
surface antigenic markers specific of their neurosecretory
activity.
There is now substantial evidence that insulin is one
important among other autoantigens tackled by various
autoreactive components of the immune system both in
animal and human type 1 diabetes [100, 101]. Moreover
insulin is the specific marker of the pancreatic islet endo-
crine ß cells. Oral, intranasal and parenteral administra-
tion of insulin or insulin-derived dominant autoantigens
have been shown to inhibit the occurrence of diabetes in
animal models of type 1 diabetes [102, 103]. However,
one cannot exclude the risk of priming or triggering auto-
immunity by peripheral administration of an autoantigen
[104]. Reprogramming the immunological tolerance that
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is thought to be broken in autoimmunity represents an
attractive strategy for the prevention of devastating au-
toimmune diseases such as multiple sclerosis, rheumatoid
arthritis or type 1 diabetes. Such reprogramming could be
based upon the natural tolerogenic properties of the thym-
ic epithelium. Instead of a classical vaccination (with
immune activation and induction of memory immuno-
competent cells), a form of tolerogenic vaccination is pro-
posed that would lead to the deletion or the anergy of
peripheral autoreactive T lymphocytes. The induction of
T-cell tolerance following peptide vaccination has already
been obtained with synthetic peptides representing cyto-
toxic CD8 epitopes of T cells oriented against tumor anti-
gens or viruses [105]. An efficient and nontoxic pre-
vention of autoimmune diseases, perhaps even their erad-
ication, could depend upon the strategic choice that will
be made between either the induction of tolerance to spe-
cific autoantigens following their parenteral administra-
tion, or the exploitation of the putative tolerogenic pro-
porties of thymic self antigens.
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